Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Prenen

Showing results (71-80 of 170) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylateHans Prenen, Jan Cools, Nicole Mentens, et al.
Journal of Geriatric Oncology|June 25, 2016
The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: A systematic reviewKatleen Fagard, Silke Leonard, Mieke Deschodt, et al.
Current Treatment Options in Oncology|May 22, 2023
New Developments in Treating RAS-Mutated Metastatic Colorectal CancerKatleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancerHans Prenen, Jef De Schutter, Bart Jacobs, et al.
JCO Global Oncology|October 3, 2024
Intersectionality Between Country, Gender and Funding in Authorship for Phase III Trials Presented at the ASCO Annual Meeting 2022Laure-Anne Teuwen, Joanna Young, Saleh Alessy, et al.
Pharmacology|March 15, 2006
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell linesHans Prenen, Gunther Guetens, Gert de Boeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutationBarbara Dewaele, Bartosz Wasag, Jan Cools, et al.
Critical Reviews in Oncology/Hematology|January 22, 2019
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatmentPeter A van Dam, Yannick Verhoeven, Xuan B Trinh, et al.
Critical Reviews in Oncology/Hematology|February 4, 2024
A systematic review of patient-derived tumor organoids generation from malignant effusionsSofie Seghers, Maxim Le Compte, Jeroen M H Hendriks, et al.
Pharmacology & Therapeutics|January 9, 2022
Targeting hedgehog signaling in pancreatic ductal adenocarcinomaDelphine Quatannens, Yannick Verhoeven, Peter Van Dam, et al.
Pageof 17

Showing results (71-80 of 170) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylateHans Prenen, Jan Cools, Nicole Mentens, et al.
Journal of Geriatric Oncology|June 25, 2016
The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: A systematic reviewKatleen Fagard, Silke Leonard, Mieke Deschodt, et al.
Current Treatment Options in Oncology|May 22, 2023
New Developments in Treating RAS-Mutated Metastatic Colorectal CancerKatleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancerHans Prenen, Jef De Schutter, Bart Jacobs, et al.
JCO Global Oncology|October 3, 2024
Intersectionality Between Country, Gender and Funding in Authorship for Phase III Trials Presented at the ASCO Annual Meeting 2022Laure-Anne Teuwen, Joanna Young, Saleh Alessy, et al.
Pharmacology|March 15, 2006
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell linesHans Prenen, Gunther Guetens, Gert de Boeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutationBarbara Dewaele, Bartosz Wasag, Jan Cools, et al.
Critical Reviews in Oncology/Hematology|January 22, 2019
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatmentPeter A van Dam, Yannick Verhoeven, Xuan B Trinh, et al.
Critical Reviews in Oncology/Hematology|February 4, 2024
A systematic review of patient-derived tumor organoids generation from malignant effusionsSofie Seghers, Maxim Le Compte, Jeroen M H Hendriks, et al.
Pharmacology & Therapeutics|January 9, 2022
Targeting hedgehog signaling in pancreatic ductal adenocarcinomaDelphine Quatannens, Yannick Verhoeven, Peter Van Dam, et al.
Pageof 17